Breaking News

Xceleron, Crystal Pharmatech in Bioavailability Pact

January 22, 2013

Aims to improve early clinical development

Xceleron, a provider of ultra-sensitive analytical technology to novel clinical designs, has partnered with Crystal Pharmatech, a China-based CRO, to offer drug developers early bioavailability data to optimize solid-state forms and formulations. The partnership will combine accelerator mass spectrometry (AMS) technology and expertise aimed at cost-effectively removing pharmacokinetic uncertainty by providing better early clinical and solid-state information.
 
“At Xceleron, we believe that technology can get life-changing drugs to people who need them, sooner and at a lower cost. This partnership will help our clients do that by efficiently and cost-effectively answering critical questions earlier,” said Dr. Michael Butler, chief executive officer of Xceleron.
 
“Having robust bioavailability and pharmacokinetic data at the outset provides a strong foundation for determining the best solid form and formulation,” said Dr. Alex Chen, chief executive officer of Crystal Pharmatech. “Each company brings significant expertise to the discussion of novel clinical outcomes.”
 

Related Compliance:

blog comments powered by Disqus
  • Top 25 Pharma and Biopharma Report

    Top 25 Pharma and Biopharma Report

    July 20, 2015
    (Based on 2014 Sales, in $U.S. Millions)

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important